Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2024

Open Access 01-12-2024 | Blinatumomab | Correspondence

Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia

Authors: Irene Urbino, Etienne Lengliné, Sandrine Valade, Marco Cerrano, Marie Sebert, Emmanuel Raffoux, Florence Rabian, Elie Azoulay, Nicolas Boissel

Published in: Critical Care | Issue 1/2024

Login to get access

Excerpt

Blinatumomab, a CD3/CD19 bispecific antibody categorized under BiTEs (bispecific T-cell engagers), has recently gained approval as a standard of care in B-cell acute lymphoblastic leukemia (B-ALL) [1, 2]. Despite its efficacy, the emergence of specific toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) with potential life-threatening grades, has been noted [3]. To date, few data are available in the literature on this emerging concern despite a very broad development of BiTEs in various diseases. This research letter aims to analyze life-threatening complications (LTCs), their rate, determinants and outcomes in a large cohort of patients treated with blinatumomab. …
Literature
1.
2.
3.
Thomas X. Real-world effectiveness and safety of blinatumomab in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Europe: 3-year results in Philadelphia chromosome-negative patients and a subset of patients with late first relaps. Blood. 2020;136(Supplement 1):38–9.CrossRef
4.
Ferreyro B. Critical illness in patients with hematologic malignancy: a population-based cohort study. Intensive Care Med,. 2021;47(10):1104–14.CrossRefPubMed
5.
Azoulay E. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021;8:e355–64.CrossRefPubMed
Metadata
Title
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia
Authors
Irene Urbino
Etienne Lengliné
Sandrine Valade
Marco Cerrano
Marie Sebert
Emmanuel Raffoux
Florence Rabian
Elie Azoulay
Nicolas Boissel
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2024
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-023-04787-x

Other articles of this Issue 1/2024

Critical Care 1/2024 Go to the issue

Review

Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: a systematic review and meta-analysis

Research

Development and validation of the tic score for early detection of traumatic coagulopathy upon hospital admission: a cohort study

Matters Arising

Albumin for sepsis-related peripheral tissue hypoperfusion

Comment

Scrutinizing mechanical circulatory support in cardiogenic shock: Have we jumped the gun?

Research

Organ donation after extracorporeal cardiopulmonary resuscitation: a nationwide retrospective cohort study

Research

Video versus direct laryngoscopy in critically ill patients: an updated systematic review and meta-analysis of randomized controlled trials